Lupin Q4 PAT seen up 17.8% at Rs 267 cr

Pharmaceutical company Lupin is expected to report a growth of 17.9% year-on-year and 14% quarter-on-quarter in its profit after tax of Rs 267 crore for the fourth quarter of FY12, according to CNBC-TV18 poll.

Revenues are seen going up by 19% YoY and 1.7% QoQ to Rs 1,850 crore during the same period.

EBITDA is likely to go up by 31.5% YoY and 9% QoQ to Rs 408.5 crore for January-March quarter of 2012.

Operating profit margin is expected to be at 22% versus 20% YoY and 20.5% QoQ.

Analysts on average expect topline growth is due to domestic sales and Geoden generic exclusivity in the US & full consolidation of Japanese company l’ROM that acquired in Q3FY12. Margins will be higher due to Geoden generic exclusivity this quarter.

Domestic business (with insulin portfolio acquired from Eli Lily) is expected to grow 30%+. In Q3, it grew 30% to Rs 520 crore and Eli Lily insulin portfolio was Rs 27 crore

US business will be boosted due to launch of Geoden. Analysts expect Rs 94 crore in revenue from Geoden this Q which will push up US + overall sales & margin. Besides US, the YoY growth will be due to currency depreciation & pick up of oral contraceptives and Suprax (seasonally strong Q for Suprax)